Specialties
weekly news, by specialtyA weekly roundup of innovation in 25 medical specialties and four therapy specialties: new technology, AI tools, devices, FDA decisions and new ways of delivering care, published every Sunday. Every item links to its sources.
Latest roundups:
Your specialty
- Family medicine
Team care with single pills lowers blood pressure in CATCH; GLP-1 drugs get optic neuropathy warning; PAHO reportedly revokes measles status
Nov. 8 to 14, 2026
- Internal medicine
FDA approves first factor XIa inhibitor after stroke; smartwatch AI flags weak pumping; GLP-1 drugs get optic neuropathy warning
Nov. 8 to 14, 2026
- Pediatrics
Reports say PAHO revoked U.S. measles elimination status; school accommodations fail in ADHD trial; Alaris kit correction made Class I
Nov. 8 to 14, 2026
- Anesthesiology
Holding ACE inhibitors or ARBs before surgery cuts hypotension; FDA alerts on Intersurgical breathing tubes and Arrow guidewires
Nov. 8 to 14, 2026
- Emergency medicine
Statewide CPR and EMS program does not raise cardiac arrest survival; AI model predicts ROSC from end-tidal CO2; breathing tubes recalled
Nov. 8 to 14, 2026
- Hospital medicine
Deprescribing stewardship gives small gain in older inpatients; FDA approves asundexian after stroke; Arrow guidewires and Alaris sets flagged
Nov. 8 to 14, 2026
- Pulmonary and critical care
Orforglipron cuts sleep apnea events in ATTAIN-OSA; FDA flags breathing tube connector risk; Alaris kit recall is Class I
Nov. 8 to 14, 2026
- Cardiology
Left bundle branch pacing cuts events in OptimPacing; AI echo drafts match human reports; Impella controller recall is Class I
Nov. 8 to 14, 2026
- Dermatology
Oral minoxidil VDPHL01 keeps hair gains at 12 months, company says; morphea and systemic sclerosis tied to higher cancer incidence
Nov. 8 to 14, 2026
- Endocrinology
FDA adds optic neuropathy warning to all GLP-1 drugs; Tandem Mobi cleared to run tubeless; survodutide meets cardiovascular safety bar
Nov. 8 to 14, 2026
- Gastroenterology
Elebsiran-tobevibart meets phase 3 hepatitis delta goal; efinopegdutide resolves MASH in phase 2b; dabigatran recanalizes portal vein thrombosis
Nov. 8 to 14, 2026
- Infectious disease
Reports say PAHO revoked U.S. measles elimination status; elebsiran-tobevibart meets hepatitis delta goal; doxycycline tied to pregnancy loss
Nov. 8 to 14, 2026
- Nephrology
FDA approves obinutuzumab as first drug for primary membranous nephropathy; dapagliflozin improves eGFR slope after heart transplant
Nov. 8 to 14, 2026
- Neurology
FDA approves first factor XIa inhibitor after stroke; MRI brain-age model predicts decline; review finds bypass triage evidence insufficient
Nov. 8 to 14, 2026
- Oncology
FDA approves durvalumab with enfortumab vedotin for bladder cancer; ACS backs regular PSA screening; camrelizumab lifts event-free survival
Nov. 8 to 14, 2026
- Psychiatry
Compass files psilocybin application for resistant depression; FDA reportedly shelves priority voucher program; lumateperone meets mania end point
Nov. 8 to 14, 2026
- General surgery
Oral antibiotics are noninferior after appendectomy for complicated appendicitis; digital follow-up tied to fewer readmissions
Nov. 8 to 14, 2026
- Neurosurgery
FDA rejects Novocure's Optune Mya for lung cancer brain metastases; Synchron pauses Stentrode enrollment; MRI model predicts meningioma grade
Nov. 8 to 14, 2026
- Obstetrics and gynecology
Early-pregnancy doxycycline tied to higher pregnancy loss risk; mobile coaching fails to cut postpartum BMI; most fibroid patients avoid retreatment
Nov. 8 to 14, 2026
- Ophthalmology
FDA adds NAION warning to all GLP-1 drugs; optic neuritis often heralds CNS inflammatory disease
Nov. 8 to 14, 2026
- Orthopedic surgery
Routine radiographs after joint replacement rarely change care; newer AI model hallucinates less; FDA approves pimicotinib for TGCT
Nov. 8 to 14, 2026
- Otolaryngology
Oral orforglipron cuts sleep apnea events in ATTAIN-OSA; preoperative grading system stratifies sinus surgery outcomes
Nov. 8 to 14, 2026
- Urology
FDA approves perioperative durvalumab plus enfortumab vedotin for bladder cancer; ACS backs regular PSA screening; bladder robot gets De Novo nod
Nov. 8 to 14, 2026
- Pathology
FDA finalizes validation guidance for emergency pathogen tests; first BD OneFlow lymphoma tests cleared; NKF report favors urinary albumin
Nov. 8 to 14, 2026
- Radiology
SNMMI-led criteria back FET PET for glioma; Bracco announces FDA-cleared aneurysm AI; Cu-64 PSMA agent gets breakthrough designation
Nov. 8 to 14, 2026
- Physical therapy
Intensive bimanual and leg therapy lifts gross motor scores in preschoolers with cerebral palsy; early brain stimulation curbs poststroke spasticity
Nov. 8 to 14, 2026
- Occupational therapy
Carpal tunnel network meta-analysis ranks shockwave first at mid-term; HABIT-ILE lifts COPM scores in preschoolers with cerebral palsy
Nov. 8 to 14, 2026
- Speech-language pathology
Dysphagia-optimized radiotherapy lowers late swallowing problems after oral cancer surgery; journal retracts complex syntax test study
Nov. 8 to 14, 2026
- Psychology and social work
Chatbots with intensive human support show an edge in very low-certainty meta-analysis; digital insomnia tools no substitute for in-person therapy
Nov. 8 to 14, 2026
Primary care
- Family medicine
Team care with single pills lowers blood pressure in CATCH; GLP-1 drugs get optic neuropathy warning; PAHO reportedly revokes measles status
Nov. 8 to 14, 2026
- Internal medicine
FDA approves first factor XIa inhibitor after stroke; smartwatch AI flags weak pumping; GLP-1 drugs get optic neuropathy warning
Nov. 8 to 14, 2026
- Pediatrics
Reports say PAHO revoked U.S. measles elimination status; school accommodations fail in ADHD trial; Alaris kit correction made Class I
Nov. 8 to 14, 2026
Hospital and acute care
- Anesthesiology
Holding ACE inhibitors or ARBs before surgery cuts hypotension; FDA alerts on Intersurgical breathing tubes and Arrow guidewires
Nov. 8 to 14, 2026
- Emergency medicine
Statewide CPR and EMS program does not raise cardiac arrest survival; AI model predicts ROSC from end-tidal CO2; breathing tubes recalled
Nov. 8 to 14, 2026
- Hospital medicine
Deprescribing stewardship gives small gain in older inpatients; FDA approves asundexian after stroke; Arrow guidewires and Alaris sets flagged
Nov. 8 to 14, 2026
- Pulmonary and critical care
Orforglipron cuts sleep apnea events in ATTAIN-OSA; FDA flags breathing tube connector risk; Alaris kit recall is Class I
Nov. 8 to 14, 2026
Medical specialties
- Cardiology
Left bundle branch pacing cuts events in OptimPacing; AI echo drafts match human reports; Impella controller recall is Class I
Nov. 8 to 14, 2026
- Dermatology
Oral minoxidil VDPHL01 keeps hair gains at 12 months, company says; morphea and systemic sclerosis tied to higher cancer incidence
Nov. 8 to 14, 2026
- Endocrinology
FDA adds optic neuropathy warning to all GLP-1 drugs; Tandem Mobi cleared to run tubeless; survodutide meets cardiovascular safety bar
Nov. 8 to 14, 2026
- Gastroenterology
Elebsiran-tobevibart meets phase 3 hepatitis delta goal; efinopegdutide resolves MASH in phase 2b; dabigatran recanalizes portal vein thrombosis
Nov. 8 to 14, 2026
- Infectious disease
Reports say PAHO revoked U.S. measles elimination status; elebsiran-tobevibart meets hepatitis delta goal; doxycycline tied to pregnancy loss
Nov. 8 to 14, 2026
- Nephrology
FDA approves obinutuzumab as first drug for primary membranous nephropathy; dapagliflozin improves eGFR slope after heart transplant
Nov. 8 to 14, 2026
- Neurology
FDA approves first factor XIa inhibitor after stroke; MRI brain-age model predicts decline; review finds bypass triage evidence insufficient
Nov. 8 to 14, 2026
- Oncology
FDA approves durvalumab with enfortumab vedotin for bladder cancer; ACS backs regular PSA screening; camrelizumab lifts event-free survival
Nov. 8 to 14, 2026
- Psychiatry
Compass files psilocybin application for resistant depression; FDA reportedly shelves priority voucher program; lumateperone meets mania end point
Nov. 8 to 14, 2026
Surgical specialties
- General surgery
Oral antibiotics are noninferior after appendectomy for complicated appendicitis; digital follow-up tied to fewer readmissions
Nov. 8 to 14, 2026
- Neurosurgery
FDA rejects Novocure's Optune Mya for lung cancer brain metastases; Synchron pauses Stentrode enrollment; MRI model predicts meningioma grade
Nov. 8 to 14, 2026
- Obstetrics and gynecology
Early-pregnancy doxycycline tied to higher pregnancy loss risk; mobile coaching fails to cut postpartum BMI; most fibroid patients avoid retreatment
Nov. 8 to 14, 2026
- Ophthalmology
FDA adds NAION warning to all GLP-1 drugs; optic neuritis often heralds CNS inflammatory disease
Nov. 8 to 14, 2026
- Orthopedic surgery
Routine radiographs after joint replacement rarely change care; newer AI model hallucinates less; FDA approves pimicotinib for TGCT
Nov. 8 to 14, 2026
- Otolaryngology
Oral orforglipron cuts sleep apnea events in ATTAIN-OSA; preoperative grading system stratifies sinus surgery outcomes
Nov. 8 to 14, 2026
- Urology
FDA approves perioperative durvalumab plus enfortumab vedotin for bladder cancer; ACS backs regular PSA screening; bladder robot gets De Novo nod
Nov. 8 to 14, 2026
Diagnostic specialties
- Pathology
FDA finalizes validation guidance for emergency pathogen tests; first BD OneFlow lymphoma tests cleared; NKF report favors urinary albumin
Nov. 8 to 14, 2026
- Radiology
SNMMI-led criteria back FET PET for glioma; Bracco announces FDA-cleared aneurysm AI; Cu-64 PSMA agent gets breakthrough designation
Nov. 8 to 14, 2026
Therapy specialties
- Physical therapy
Intensive bimanual and leg therapy lifts gross motor scores in preschoolers with cerebral palsy; early brain stimulation curbs poststroke spasticity
Nov. 8 to 14, 2026
- Occupational therapy
Carpal tunnel network meta-analysis ranks shockwave first at mid-term; HABIT-ILE lifts COPM scores in preschoolers with cerebral palsy
Nov. 8 to 14, 2026
- Speech-language pathology
Dysphagia-optimized radiotherapy lowers late swallowing problems after oral cancer surgery; journal retracts complex syntax test study
Nov. 8 to 14, 2026
- Psychology and social work
Chatbots with intensive human support show an edge in very low-certainty meta-analysis; digital insomnia tools no substitute for in-person therapy
Nov. 8 to 14, 2026
About these roundups
Each roundup covers innovation in the specialty announced or published in the seven days before it comes out, Sunday through Saturday: new technology and devices, artificial intelligence tools and the studies that test them, decisions by the Food and Drug Administration on new technology, and new ways of delivering care. Routine clinical news (a new drug, a treatment trial, a guideline or a shortage) is left out unless a new technology or a new care model is its subject. A roundup runs five to seven items in a busy week and fewer in a quiet one. Each specialty's roundup is also read aloud as a weekly podcast.
Items come from primary sources where possible (the journal article, the agency notice, the society statement), with news coverage linked as a second source, and every roundup is checked against its sources before it is published. Company announcements and results that have not been peer reviewed are identified as such. The roundups are news, not medical advice.
Free or Pro. A free account opens every article and comes with the Friday letter by email. Pro adds every full tool review and the whole law map.